Review



trichrome staining  (Beyotime)


Bioz Verified Symbol Beyotime is a verified supplier
Bioz Manufacturer Symbol Beyotime manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    Beyotime trichrome staining
    Trichrome Staining, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 364 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+kit/Masson's+Trichrome+Staining+Kit/pm42862847-260-1-16
    Average 99 stars, based on 364 article reviews
    trichrome staining - by Bioz Stars, 2026-10
    99/100 stars

    Images

    Related Articles

    Staining:

    Article Title: Early-in-life inhalation exposure to diesel exhaust enhanced high fat diet-induced atherosclerosis via CD36-NLRP3 inflammasome / TXNIP.
    Article Snippet: .. Hematoxylin & eosin (HE) staining of aorta sections was performed with a staining kit from Beyotime (Beijing, China) following manufacturer-provided protocol. .. Pictures of aorta tissue sections (four per animal) were taken with an Olympus BX53F2 microscope (Olympus, Japan).

    Article Title: Self-healing hydrogels incorporating hyaluronic acid, poly(Acrylic Acid), and ferric ions for flexible sensing and wound healing.
    Article Snippet: In this study, novel hydrogels based on polyacrylic acid, hyaluronic acid, and ferric ions as non-covalent crosslinkers were synthesized via a one-pot method.. The influence of hyaluronic acid on the mechanical and functional properties of the hydrogels was systematically evaluated.. Rheological and mechanical analyses revealed that the incorporation of hyaluronic acid significantly enhances tensile strength, toughness, and elasticity, while maintaining a robust polymer network.

    Article Title: Berberine augments the secretory function of salivary gland in homeostasis and after radiation exposure
    Article Snippet: .. The tissue sections were mounted onto microscope slides and then stained with conventional hematoxylin and eosin (H&E) with a commercial staining kit (C0105M, Beyotime, China). ..

    Article Title: Endothelial cells as early therapeutic targets in chronic obstructive pulmonary disease: Insights into Tongxinluo's multiple protective mechanisms against cigarette smoke-induced lung injury.
    Article Snippet: .. Then, the lung tissues were dehydrated in a gradient of ethanol solutions, embedded in paraffin, sectioned and stained with hematoxylin and eosin (H&E) using a staining kit (Beyotime, Shanghai, China). .. Finally, the slices were photographed under a fully automated biological microscope (Leica DM6000B, Wetzlar, Germany).

    Article Title: A novel regulatory circuit of ATG4B and SESN3 promotes T cell leukemogenesis.
    Article Snippet: .. 133 134 Monodansylcadaverine (MDC) staining 135 MDC staining assay was performed using a staining kit (C3018M, Beyotime, Shanghai, 136 China) following the manufacturer’s instruction. ..

    Article Title: Fucoidan alleviates chemotherapy-induced steatohepatitis by regulating the gut-liver axis.
    Article Snippet: For immunohistochemical analysis, the colon sections were first dewaxed in environmentally friendly dewaxing transparent (G1128, Servicebio), rehydrated through a descending ethanol gradient, and rinsed with phosphate-buffered saline (PBS). .. Hematoxylin and eosin (H&E) staining was performed using the staining kit (C0105S, Beyotime Biotechnology) according to the manufacturer's protocol. ..

    Article Title: Rosmarinic acid alleviates doxorubicin-induced cellular senescence and cardiotoxicity by targeting the 14-3-3/Foxo1 signaling axis.
    Article Snippet: Background: Doxorubicin (DOX)-induced cardiotoxicity remains a major clinical challenge in cancer chemotherapy, with cardiomyocyte senescence as an emerging pathogenic mechanism.. Rosmarinic Acid (RA), a polyphenolic compound with demonstrated anti-aging properties; however, its precise molecular mechanisms in targeting cellular senescence remain to be fully elucidated.. Purpose: This research aimed to explore how RA affects cardiomyocyte senescence and its treatment efficacy in DOX-induced cardiotoxicity.

    Article Title: iPSC-MSC-derived exosomes attenuate pulmonary fibrosis by inhibiting pulmonary fibroblast activation via delivery of TRIM31.
    Article Snippet: Idiopathic pulmonary fibrosis (IPF) is a serious and progressive lung disease characterized by devastating and progressive fibrosis.. Treatment is unsatisfactory.. There is accumulating evidence that transplantation of mesenchymal stem cell derived exosomes (MSC-EXOs) protects against IPF.

    Microscopy:

    Article Title: Berberine augments the secretory function of salivary gland in homeostasis and after radiation exposure
    Article Snippet: .. The tissue sections were mounted onto microscope slides and then stained with conventional hematoxylin and eosin (H&E) with a commercial staining kit (C0105M, Beyotime, China). ..

    H&E Stain:

    Article Title: Fucoidan alleviates chemotherapy-induced steatohepatitis by regulating the gut-liver axis.
    Article Snippet: For immunohistochemical analysis, the colon sections were first dewaxed in environmentally friendly dewaxing transparent (G1128, Servicebio), rehydrated through a descending ethanol gradient, and rinsed with phosphate-buffered saline (PBS). .. Hematoxylin and eosin (H&E) staining was performed using the staining kit (C0105S, Beyotime Biotechnology) according to the manufacturer's protocol. ..

    Histopathology:

    Article Title: iPSC-MSC-derived exosomes attenuate pulmonary fibrosis by inhibiting pulmonary fibroblast activation via delivery of TRIM31.
    Article Snippet: Idiopathic pulmonary fibrosis (IPF) is a serious and progressive lung disease characterized by devastating and progressive fibrosis.. Treatment is unsatisfactory.. There is accumulating evidence that transplantation of mesenchymal stem cell derived exosomes (MSC-EXOs) protects against IPF.



    Similar Products

    99
    Beyotime trichrome staining
    Trichrome Staining, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+kit/Masson's+Trichrome+Staining+Kit/pm42862847-260-1-16
    Average 99 stars, based on 1 article reviews
    trichrome staining - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Beyotime hematoxylin
    Hematoxylin, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+kit/Hematoxylin+and+Eosin+Staining+Kit/pmc13655258-279-0-11
    Average 99 stars, based on 1 article reviews
    hematoxylin - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Beyotime senescence associated β gal
    ( A ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM). CCK8 assays reveal the cell growth under PAL (0.5 μM) or ABE (0.1 μM) treatment ( N = 3 biological replicates). ( B ) CCK8 assays calculating IC 50 values of SUV-ASO-Ms in MCF7-TAMR, MCF7-PALR, and MCF7-ABER cells ( N = 3 biological replicates). ( C ) Synergy Finder is calculating ZIP scores in MCF7-TAMR to study the synergistic effect between SUV-ASO-Ms and CDK4/6i (PAL and ABE). ( D and E ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM) alone or in combination with CDK4/6i (PAL, 0.5 μM and ABE, 0.1 μM). Flow cytometry analysis (D) <t>and</t> <t>β-Gal</t> activity assays (20× magnification) (E) showing the cell cycle distribution and senescence of the cells. ( F ) Schematic depicting the experimental design of the MCF7-ABER xenograft tumors conducted to assess the efficacy of SUV-ASO2-M or a combination of SUV-ASO2-M with ABE in vivo. ( G to I ) After being treated with Ctr-ASO-M or SUV-ASO2-M in combination with Veh or ABE, the tumor growth curves (G), the harvested tumors (H), and the tumor weight (I) were measured. ( J and K ) RT-qPCR and Western blotting detection of SUV39H2 mRNA (J) and protein (K) in tumors from xenografts. ( L ) IHC staining of p21 in tumors from xenografts. H scores were calculated for p21 in all samples. Data were presented as means ± SD [(A to E), N = 3 biological replicates; (G), (I), (J) to (L), N = 5 biological replicates]. The P values were calculated by one-way ANOVA followed by Tukey’s test for multiple-group comparison.
    Senescence Associated β Gal, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+kit/Senescence+%CE%B2-Galactosidase+Staining+Kit/pmc13651863-271-5-10
    Average 99 stars, based on 1 article reviews
    senescence associated β gal - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    96
    Vector Laboratories immunohistochemistry ihc staining
    ( A ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM). CCK8 assays reveal the cell growth under PAL (0.5 μM) or ABE (0.1 μM) treatment ( N = 3 biological replicates). ( B ) CCK8 assays calculating IC 50 values of SUV-ASO-Ms in MCF7-TAMR, MCF7-PALR, and MCF7-ABER cells ( N = 3 biological replicates). ( C ) Synergy Finder is calculating ZIP scores in MCF7-TAMR to study the synergistic effect between SUV-ASO-Ms and CDK4/6i (PAL and ABE). ( D and E ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM) alone or in combination with CDK4/6i (PAL, 0.5 μM and ABE, 0.1 μM). Flow cytometry analysis (D) <t>and</t> <t>β-Gal</t> activity assays (20× magnification) (E) showing the cell cycle distribution and senescence of the cells. ( F ) Schematic depicting the experimental design of the MCF7-ABER xenograft tumors conducted to assess the efficacy of SUV-ASO2-M or a combination of SUV-ASO2-M with ABE in vivo. ( G to I ) After being treated with Ctr-ASO-M or SUV-ASO2-M in combination with Veh or ABE, the tumor growth curves (G), the harvested tumors (H), and the tumor weight (I) were measured. ( J and K ) RT-qPCR and Western blotting detection of SUV39H2 mRNA (J) and protein (K) in tumors from xenografts. ( L ) IHC staining of p21 in tumors from xenografts. H scores were calculated for p21 in all samples. Data were presented as means ± SD [(A to E), N = 3 biological replicates; (G), (I), (J) to (L), N = 5 biological replicates]. The P values were calculated by one-way ANOVA followed by Tukey’s test for multiple-group comparison.
    Immunohistochemistry Ihc Staining, supplied by Vector Laboratories, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+kit/DAB+Peroxidase+(HRP)+Substrate+Kit+(with+Nickel)%2C+3%2C3%E2%80%99-diaminobenzidine/pm42855520-275-0-10
    Average 96 stars, based on 1 article reviews
    immunohistochemistry ihc staining - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Valiant Co Ltd 02195458 cf foxp3 transcription factor staining kit ebioscience 00 5523 00 paraformaldehyde
    ( A ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM). CCK8 assays reveal the cell growth under PAL (0.5 μM) or ABE (0.1 μM) treatment ( N = 3 biological replicates). ( B ) CCK8 assays calculating IC 50 values of SUV-ASO-Ms in MCF7-TAMR, MCF7-PALR, and MCF7-ABER cells ( N = 3 biological replicates). ( C ) Synergy Finder is calculating ZIP scores in MCF7-TAMR to study the synergistic effect between SUV-ASO-Ms and CDK4/6i (PAL and ABE). ( D and E ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM) alone or in combination with CDK4/6i (PAL, 0.5 μM and ABE, 0.1 μM). Flow cytometry analysis (D) <t>and</t> <t>β-Gal</t> activity assays (20× magnification) (E) showing the cell cycle distribution and senescence of the cells. ( F ) Schematic depicting the experimental design of the MCF7-ABER xenograft tumors conducted to assess the efficacy of SUV-ASO2-M or a combination of SUV-ASO2-M with ABE in vivo. ( G to I ) After being treated with Ctr-ASO-M or SUV-ASO2-M in combination with Veh or ABE, the tumor growth curves (G), the harvested tumors (H), and the tumor weight (I) were measured. ( J and K ) RT-qPCR and Western blotting detection of SUV39H2 mRNA (J) and protein (K) in tumors from xenografts. ( L ) IHC staining of p21 in tumors from xenografts. H scores were calculated for p21 in all samples. Data were presented as means ± SD [(A to E), N = 3 biological replicates; (G), (I), (J) to (L), N = 5 biological replicates]. The P values were calculated by one-way ANOVA followed by Tukey’s test for multiple-group comparison.
    02195458 Cf Foxp3 Transcription Factor Staining Kit Ebioscience 00 5523 00 Paraformaldehyde, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+kit/Paraformaldehyde/pm42855519-207-483-481
    Average 96 stars, based on 1 article reviews
    02195458 cf foxp3 transcription factor staining kit ebioscience 00 5523 00 paraformaldehyde - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    99
    Dojindo Labs ferroorange staining kit
    ( A ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM). CCK8 assays reveal the cell growth under PAL (0.5 μM) or ABE (0.1 μM) treatment ( N = 3 biological replicates). ( B ) CCK8 assays calculating IC 50 values of SUV-ASO-Ms in MCF7-TAMR, MCF7-PALR, and MCF7-ABER cells ( N = 3 biological replicates). ( C ) Synergy Finder is calculating ZIP scores in MCF7-TAMR to study the synergistic effect between SUV-ASO-Ms and CDK4/6i (PAL and ABE). ( D and E ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM) alone or in combination with CDK4/6i (PAL, 0.5 μM and ABE, 0.1 μM). Flow cytometry analysis (D) <t>and</t> <t>β-Gal</t> activity assays (20× magnification) (E) showing the cell cycle distribution and senescence of the cells. ( F ) Schematic depicting the experimental design of the MCF7-ABER xenograft tumors conducted to assess the efficacy of SUV-ASO2-M or a combination of SUV-ASO2-M with ABE in vivo. ( G to I ) After being treated with Ctr-ASO-M or SUV-ASO2-M in combination with Veh or ABE, the tumor growth curves (G), the harvested tumors (H), and the tumor weight (I) were measured. ( J and K ) RT-qPCR and Western blotting detection of SUV39H2 mRNA (J) and protein (K) in tumors from xenografts. ( L ) IHC staining of p21 in tumors from xenografts. H scores were calculated for p21 in all samples. Data were presented as means ± SD [(A to E), N = 3 biological replicates; (G), (I), (J) to (L), N = 5 biological replicates]. The P values were calculated by one-way ANOVA followed by Tukey’s test for multiple-group comparison.
    Ferroorange Staining Kit, supplied by Dojindo Labs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+kit/FerroOrange/10__1038_slash_s41598___026___74118___x-95-12-15
    Average 99 stars, based on 1 article reviews
    ferroorange staining kit - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Beyotime β galactosidase staining kit
    ( A ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM). CCK8 assays reveal the cell growth under PAL (0.5 μM) or ABE (0.1 μM) treatment ( N = 3 biological replicates). ( B ) CCK8 assays calculating IC 50 values of SUV-ASO-Ms in MCF7-TAMR, MCF7-PALR, and MCF7-ABER cells ( N = 3 biological replicates). ( C ) Synergy Finder is calculating ZIP scores in MCF7-TAMR to study the synergistic effect between SUV-ASO-Ms and CDK4/6i (PAL and ABE). ( D and E ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM) alone or in combination with CDK4/6i (PAL, 0.5 μM and ABE, 0.1 μM). Flow cytometry analysis (D) <t>and</t> <t>β-Gal</t> activity assays (20× magnification) (E) showing the cell cycle distribution and senescence of the cells. ( F ) Schematic depicting the experimental design of the MCF7-ABER xenograft tumors conducted to assess the efficacy of SUV-ASO2-M or a combination of SUV-ASO2-M with ABE in vivo. ( G to I ) After being treated with Ctr-ASO-M or SUV-ASO2-M in combination with Veh or ABE, the tumor growth curves (G), the harvested tumors (H), and the tumor weight (I) were measured. ( J and K ) RT-qPCR and Western blotting detection of SUV39H2 mRNA (J) and protein (K) in tumors from xenografts. ( L ) IHC staining of p21 in tumors from xenografts. H scores were calculated for p21 in all samples. Data were presented as means ± SD [(A to E), N = 3 biological replicates; (G), (I), (J) to (L), N = 5 biological replicates]. The P values were calculated by one-way ANOVA followed by Tukey’s test for multiple-group comparison.
    β Galactosidase Staining Kit, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+kit/Lysosomal+%CE%B2-Galactosidase+Staining+Kit/pm42850481-105-31-34
    Average 99 stars, based on 1 article reviews
    β galactosidase staining kit - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec dapi staining solution
    ( A ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM). CCK8 assays reveal the cell growth under PAL (0.5 μM) or ABE (0.1 μM) treatment ( N = 3 biological replicates). ( B ) CCK8 assays calculating IC 50 values of SUV-ASO-Ms in MCF7-TAMR, MCF7-PALR, and MCF7-ABER cells ( N = 3 biological replicates). ( C ) Synergy Finder is calculating ZIP scores in MCF7-TAMR to study the synergistic effect between SUV-ASO-Ms and CDK4/6i (PAL and ABE). ( D and E ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM) alone or in combination with CDK4/6i (PAL, 0.5 μM and ABE, 0.1 μM). Flow cytometry analysis (D) <t>and</t> <t>β-Gal</t> activity assays (20× magnification) (E) showing the cell cycle distribution and senescence of the cells. ( F ) Schematic depicting the experimental design of the MCF7-ABER xenograft tumors conducted to assess the efficacy of SUV-ASO2-M or a combination of SUV-ASO2-M with ABE in vivo. ( G to I ) After being treated with Ctr-ASO-M or SUV-ASO2-M in combination with Veh or ABE, the tumor growth curves (G), the harvested tumors (H), and the tumor weight (I) were measured. ( J and K ) RT-qPCR and Western blotting detection of SUV39H2 mRNA (J) and protein (K) in tumors from xenografts. ( L ) IHC staining of p21 in tumors from xenografts. H scores were calculated for p21 in all samples. Data were presented as means ± SD [(A to E), N = 3 biological replicates; (G), (I), (J) to (L), N = 5 biological replicates]. The P values were calculated by one-way ANOVA followed by Tukey’s test for multiple-group comparison.
    Dapi Staining Solution, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/staining+kit/MACSima+Stain+Support+Kit%2C+human/10__1038_slash_s42003___026___11109___8-243-16-19
    Average 94 stars, based on 1 article reviews
    dapi staining solution - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM). CCK8 assays reveal the cell growth under PAL (0.5 μM) or ABE (0.1 μM) treatment ( N = 3 biological replicates). ( B ) CCK8 assays calculating IC 50 values of SUV-ASO-Ms in MCF7-TAMR, MCF7-PALR, and MCF7-ABER cells ( N = 3 biological replicates). ( C ) Synergy Finder is calculating ZIP scores in MCF7-TAMR to study the synergistic effect between SUV-ASO-Ms and CDK4/6i (PAL and ABE). ( D and E ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM) alone or in combination with CDK4/6i (PAL, 0.5 μM and ABE, 0.1 μM). Flow cytometry analysis (D) and β-Gal activity assays (20× magnification) (E) showing the cell cycle distribution and senescence of the cells. ( F ) Schematic depicting the experimental design of the MCF7-ABER xenograft tumors conducted to assess the efficacy of SUV-ASO2-M or a combination of SUV-ASO2-M with ABE in vivo. ( G to I ) After being treated with Ctr-ASO-M or SUV-ASO2-M in combination with Veh or ABE, the tumor growth curves (G), the harvested tumors (H), and the tumor weight (I) were measured. ( J and K ) RT-qPCR and Western blotting detection of SUV39H2 mRNA (J) and protein (K) in tumors from xenografts. ( L ) IHC staining of p21 in tumors from xenografts. H scores were calculated for p21 in all samples. Data were presented as means ± SD [(A to E), N = 3 biological replicates; (G), (I), (J) to (L), N = 5 biological replicates]. The P values were calculated by one-way ANOVA followed by Tukey’s test for multiple-group comparison.

    Journal: Science Advances

    Article Title: Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21

    doi: 10.1126/sciadv.aea2001

    Figure Lengend Snippet: ( A ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM). CCK8 assays reveal the cell growth under PAL (0.5 μM) or ABE (0.1 μM) treatment ( N = 3 biological replicates). ( B ) CCK8 assays calculating IC 50 values of SUV-ASO-Ms in MCF7-TAMR, MCF7-PALR, and MCF7-ABER cells ( N = 3 biological replicates). ( C ) Synergy Finder is calculating ZIP scores in MCF7-TAMR to study the synergistic effect between SUV-ASO-Ms and CDK4/6i (PAL and ABE). ( D and E ) MCF7-PALR and MCF7-ABER cells were treated with Ctr-ASO-M or SUV-ASO-Ms (0.1 μM) alone or in combination with CDK4/6i (PAL, 0.5 μM and ABE, 0.1 μM). Flow cytometry analysis (D) and β-Gal activity assays (20× magnification) (E) showing the cell cycle distribution and senescence of the cells. ( F ) Schematic depicting the experimental design of the MCF7-ABER xenograft tumors conducted to assess the efficacy of SUV-ASO2-M or a combination of SUV-ASO2-M with ABE in vivo. ( G to I ) After being treated with Ctr-ASO-M or SUV-ASO2-M in combination with Veh or ABE, the tumor growth curves (G), the harvested tumors (H), and the tumor weight (I) were measured. ( J and K ) RT-qPCR and Western blotting detection of SUV39H2 mRNA (J) and protein (K) in tumors from xenografts. ( L ) IHC staining of p21 in tumors from xenografts. H scores were calculated for p21 in all samples. Data were presented as means ± SD [(A to E), N = 3 biological replicates; (G), (I), (J) to (L), N = 5 biological replicates]. The P values were calculated by one-way ANOVA followed by Tukey’s test for multiple-group comparison.

    Article Snippet: Senescence was measured by the Senescence-Associated β-gal (SA-β-gal) Stain Kit (Beyotime, C0602).

    Techniques: Flow Cytometry, Analysis, Activity Assay, Xenograft Assay, In Vivo, Quantitative RT-PCR, Western Blot, Immunohistochemistry, Comparison

    ( A ) H3K9me3 signals (CUT&Tag) around promoters and enhancers in MCF7-ABER cells treated with Ctr-ASO-M or SUV-ASO2-M (0.1 μM). ( B ) RAD21 signals (ChIP-seq) around enhancers in MCF7 cells ( GSE25021 and GSE72082 datasets). ( C ) RAD21 signals (ChIP-seq) around SUV39H2-dependent and independent H3K9me3 peaks. ( D ) A volcano plot of DEGs between the RAD21 overexpression and the control group (MCF7-ABER). ( E ) GSEA of transcriptome between RAD21 overexpression and the control. ( F and G ) Western blotting (F) and RT-qPCR (G) detection of RAD21 and p21 protein levels, and p21 mRNA levels in MCF7-PALR and MCF7-ABER cells with RAD21 overexpression. ( H ) IGV visualization of H3K9me3, RAD21, STAG1, and SMC1A signals in the p21 promoter ( p21 -Pro) and distal enhancer ( p21 -SE). Blue box: cohesin binding site; gray box: differential H3K9me3 peak. ( I and J ) ChIP-qPCR of H3K9me3 (I) and RAD21 (J) in p21 -Pro and p21 -SE of MCF7-PALR and MCF7-ABER cells treated with Ctr-ASO-M or SUV-ASO2-M (0.1 μM). ( K ) ChIP-qPCR of SUV39H2 in p21 -Pro and p21 -SE of MCF7-PALR and MCF7-ABER cells. ( L ) Western blotting of RAD21, SUV39H2, and p21 protein levels in MCF7-ABER cells transfected with Ctr siRNA or RAD21 siRNA and then treated with Ctr-ASO-M or SUV-ASO2-M (0.1 μM). ( M ) MCF7-ABER cells were transfected with Ctr siRNA or RAD21 siRNA1. CCK8 assays showing cell growth in cells treated with Ctr-ASO-M or SUV-ASO2-M (0.1 μM) in combination with ABE (0.1 μM). ( N ) MCF7-ABER cells were transfected with Ctr siRNA or RAD21 siRNA1. β-Gal activity assays (20× magnification) revealing the senescent cells treated with Ctr-ASO-M or SUV-ASO2-M (0.1 μM). In (F), (G), (I) to (N), data were presented as means ± SD ( N = 3 biological replicates). The P values were calculated using a two-tailed unpaired Student’s t test for two-group comparison and one-way ANOVA followed by Tukey’s test for multiple-group comparisons.

    Journal: Science Advances

    Article Title: Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21

    doi: 10.1126/sciadv.aea2001

    Figure Lengend Snippet: ( A ) H3K9me3 signals (CUT&Tag) around promoters and enhancers in MCF7-ABER cells treated with Ctr-ASO-M or SUV-ASO2-M (0.1 μM). ( B ) RAD21 signals (ChIP-seq) around enhancers in MCF7 cells ( GSE25021 and GSE72082 datasets). ( C ) RAD21 signals (ChIP-seq) around SUV39H2-dependent and independent H3K9me3 peaks. ( D ) A volcano plot of DEGs between the RAD21 overexpression and the control group (MCF7-ABER). ( E ) GSEA of transcriptome between RAD21 overexpression and the control. ( F and G ) Western blotting (F) and RT-qPCR (G) detection of RAD21 and p21 protein levels, and p21 mRNA levels in MCF7-PALR and MCF7-ABER cells with RAD21 overexpression. ( H ) IGV visualization of H3K9me3, RAD21, STAG1, and SMC1A signals in the p21 promoter ( p21 -Pro) and distal enhancer ( p21 -SE). Blue box: cohesin binding site; gray box: differential H3K9me3 peak. ( I and J ) ChIP-qPCR of H3K9me3 (I) and RAD21 (J) in p21 -Pro and p21 -SE of MCF7-PALR and MCF7-ABER cells treated with Ctr-ASO-M or SUV-ASO2-M (0.1 μM). ( K ) ChIP-qPCR of SUV39H2 in p21 -Pro and p21 -SE of MCF7-PALR and MCF7-ABER cells. ( L ) Western blotting of RAD21, SUV39H2, and p21 protein levels in MCF7-ABER cells transfected with Ctr siRNA or RAD21 siRNA and then treated with Ctr-ASO-M or SUV-ASO2-M (0.1 μM). ( M ) MCF7-ABER cells were transfected with Ctr siRNA or RAD21 siRNA1. CCK8 assays showing cell growth in cells treated with Ctr-ASO-M or SUV-ASO2-M (0.1 μM) in combination with ABE (0.1 μM). ( N ) MCF7-ABER cells were transfected with Ctr siRNA or RAD21 siRNA1. β-Gal activity assays (20× magnification) revealing the senescent cells treated with Ctr-ASO-M or SUV-ASO2-M (0.1 μM). In (F), (G), (I) to (N), data were presented as means ± SD ( N = 3 biological replicates). The P values were calculated using a two-tailed unpaired Student’s t test for two-group comparison and one-way ANOVA followed by Tukey’s test for multiple-group comparisons.

    Article Snippet: Senescence was measured by the Senescence-Associated β-gal (SA-β-gal) Stain Kit (Beyotime, C0602).

    Techniques: ChIP-sequencing, Over Expression, Control, Western Blot, Quantitative RT-PCR, Binding Assay, ChIP-qPCR, Transfection, Activity Assay, Two Tailed Test, Comparison